Dr. Lal Path Labs Ltd.
LALPATHLAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹744.92.
Piotroski F-score 6/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%21.5%
- ✓Low debt (D/E < 0.5)0.08x
- ✓Positive free cash flow
- ✓Revenue growth > 10%17%
- ✕Earnings growing-15%
- ✓Net margin ≥ 10%18.3%
- ✓Current ratio > 1.53.48
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 34.13
- ✕Piotroski ≥ 76/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (21.5%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (18.3%).
- •Financially solid — Altman Z 34.13.
Opportunities
- •Revenue growing (17% YoY).
Threats
- •Earnings contracting year on year.
- •Trades ~42% above our estimated fair value.
About Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.